Pharmaceuticals
2025Fiscal year
Companies 160
Median of average pay per registered director · KRW 283 million
| Company | Notes | ||||
|---|---|---|---|---|---|
| April Bio | KRW 201 million | KRW 282 million | 2 | 27 | |
| Orum Therapeutics | KRW 174 million | KRW 455 million | 3 | 21 | |
| Ligachem Biosciences | KRW 157 million | KRW 194 million | 5 | 180 | |
| Vi Gen Cell | KRW 155 million | KRW 197 million | 3 | 43 | |
| Chongkundang Holdings | KRW 142 million | KRW 301 million | 2 | 38 | Denominator mismatch flagged |
| Qurient | KRW 139 million | KRW 190 million | 6 | 32 | |
| Dong-A Pharmaceutical | KRW 136 million | KRW 534 million | 2 | 77 | Filer note attached |
| G2 Gbio | KRW 125 million | KRW 238 million | 4 | 48 | |
| SK Biopharmaceuticals | KRW 121 million | KRW 663 million | 3 | 272 | Filer note attached |
| Immuneoncia Therapeutics | KRW 115 million | KRW 344 million | 2 | 22 | |
| Samsung Biologics | KRW 112 million | KRW 2,831 million | 3 | 5,455 | |
| Celltrion | KRW 102 million | KRW 1,466 million | 4 | 3,153 | |
| Yuhan | KRW 99 million | KRW 684 million | 3 | 2,153 | |
| Daewon Pharmaceutical | KRW 86 million | KRW 542 million | 3 | 1,349 | |
| Hanmi Pharm | KRW 86 million | KRW 408 million | 6 | 2,382 | |
| Ilyang Pharmaceutical | KRW 85 million | KRW 259 million | 3 | 665 | |
| Curacle | KRW 84 million | KRW 198 million | 4 | 31 | |
| HK Inno.N | KRW 83 million | KRW 1,059 million | 3 | 1,723 | |
| Hanall Biopharma | KRW 82 million | KRW 352 million | 4 | 315 | |
| Samjin Pharmaceutical | KRW 82 million | KRW 1,518 million | 5 | 819 | Filer note attached |
| Voronoi | KRW 81 million | KRW 137 million | 3 | 149 | |
| Chong Kun Dang | KRW 81 million | KRW 282 million | 5 | 2,304 | Filer note attached |
| Donga ST | KRW 79 million | KRW 570 million | 3 | 1,685 | |
| Myungin Pharm | KRW 79 million | KRW 436 million | 3 | 532 | |
| Onconic Therapeutics | KRW 79 million | KRW 447 million | 2 | 38 | |
| GC | KRW 78 million | KRW 1,361 million | 3 | 163 | |
| Kwangdong Pharmaceutical | KRW 78 million | KRW 591 million | 3 | 1,022 | |
| Inventera | KRW 78 million | KRW 342 million | 2 | 18 | |
| Ildong Pharm | KRW 78 million | KRW 366 million | 4 | 1,104 | |
| Handok | KRW 78 million | KRW 396 million | 5 | 951 | |
| Daewoong Pharmaceutical | KRW 78 million | KRW 558 million | 3 | 1,794 | |
| Celltrion Pharm | KRW 77 million | KRW 442 million | 3 | 1,006 | |
| Shinpoong Pharmaceutical | KRW 77 million | KRW 170 million | 2 | 792 | |
| Reyon Pharmaceutical | KRW 76 million | KRW 457 million | 2 | 457 | |
| Sillajen | KRW 76 million | KRW 178 million | 2 | 56 | |
| Whanin Pharm | KRW 75 million | KRW 734 million | 2 | 671 | |
| JW Shinyak | KRW 75 million | KRW 181 million | 2 | 173 | |
| Kyongbo Pharmaceutical | KRW 75 million | KRW 281 million | 3 | 571 | |
| Parataxis Korea | KRW 75 million | KRW 166 million | 3 | 16 | |
| Pharm Gen Science | KRW 74 million | KRW 367 million | 6 | 229 | |
| JW Holdings | KRW 74 million | KRW 457 million | 4 | 128 | |
| Kainos Medicine | KRW 74 million | KRW 164 million | 2 | 15 | |
| Jeil Pharma Holdings | KRW 73 million | KRW 222 million | 4 | 40 | |
| GC Biopharma | KRW 73 million | KRW 649 million | 3 | 2,351 | |
| Hanmi Science | KRW 73 million | KRW 549 million | 7 | 489 | |
| Boryung | KRW 72 million | KRW 1,429 million | 4 | 1,645 | Filer note attached |
| Hyundai Pharm | KRW 72 million | KRW 438 million | 1 | 399 | Fiscal year end 11 |
| Dongwha Pharm | KRW 72 million | KRW 297 million | 4 | 838 | |
| Shaperon | KRW 71 million | KRW 406 million | 1 | 53 | |
| JW Lifescience | KRW 70 million | KRW 172 million | 1 | 319 | |
| Aminologics | KRW 69 million | KRW 100 million | 4 | 41 | |
| Yungjin Pharm | KRW 69 million | KRW 659 million | 2 | 626 | |
| Daewoong | KRW 69 million | KRW 187 million | 2 | 413 | |
| Kukjeon | KRW 69 million | KRW 291 million | 3 | 172 | |
| Kukje Pharma | KRW 68 million | KRW 2,112 million | 3 | 272 | |
| GC Well Being | KRW 68 million | KRW 198 million | 4 | 330 | Denominator mismatch flagged |
| CKD Bio | KRW 68 million | KRW 112 million | 3 | 533 | |
| Dong Kook Pharmaceutical | KRW 68 million | KRW 711 million | 2 | 1,306 | |
| Samil Pharmaceutical | KRW 68 million | KRW 497 million | 4 | 614 | |
| ST Pharm | KRW 68 million | KRW 334 million | 2 | 780 | |
| Korea Pharma | KRW 68 million | KRW 337 million | 3 | 284 | |
| SK Bioscience | KRW 68 million | KRW 1,084 million | 3 | 1,129 | |
| Aribio Lab | KRW 67 million | KRW 73 million | 3 | 49 | |
| Korea United Pharm | KRW 67 million | KRW 836 million | 5 | 902 | |
| Penetrium Bio | KRW 66 million | KRW 94 million | 6 | 110 | |
| Samsung Pharmaceutical | KRW 66 million | KRW 146 million | 4 | 87 | |
| Green Lifescience | KRW 66 million | KRW 132 million | 2 | 63 | |
| SAM Chun Dang Pharm | KRW 66 million | KRW 66 million | 5 | 436 | |
| Seoul Pharma | KRW 66 million | KRW 57 million | 4 | 132 | |
| Metacare | KRW 66 million | KRW 49 million | 3 | 32 | |
| MFC | KRW 64 million | KRW 281 million | 3 | 65 | |
| Jeil Pharm | KRW 64 million | KRW 302 million | 5 | 1,011 | |
| JW Pharmaceutical | KRW 64 million | KRW 544 million | 3 | 1,106 | |
| IM Biologics | KRW 63 million | KRW 159 million | 4 | 41 | |
| Myung Moon Pharm | KRW 63 million | KRW 651 million | 2 | 309 | |
| CMG Pharmaceutical | KRW 63 million | KRW 93 million | 4 | 206 | |
| Bukwang Pharmaceutical | KRW 63 million | KRW 357 million | 2 | 650 | Filer note attached |
| Choa Pharmaceutical | KRW 62 million | KRW 452 million | 3 | 243 | |
| Daehan Nupharm | KRW 62 million | KRW 712 million | 2 | 393 | |
| Ildong Holdings | KRW 62 million | KRW 572 million | 4 | 84 | |
| Yuyu Pharma | KRW 62 million | KRW 581 million | 2 | 248 | |
| Huons Global | KRW 62 million | KRW 383 million | 3 | 121 | |
| Daihan Pharmaceutical | KRW 62 million | KRW 257 million | 3 | 737 | |
| Oscotec | KRW 62 million | KRW 476 million | 3 | 57 | |
| Hwail Pharm | KRW 62 million | KRW 212 million | 3 | 145 | |
| Sinsin Pharmaceutical | KRW 61 million | KRW 372 million | 2 | 369 | |
| Kolon Life Science | KRW 61 million | KRW 590 million | 3 | 454 | Filer note attached |
| Inventage Lab | KRW 61 million | KRW 266 million | 5 | 73 | |
| ISU Abxis | KRW 60 million | KRW 342 million | 3 | 190 | |
| High Tech Pharm | KRW 60 million | KRW 233 million | 3 | 130 | |
| Optipharm | KRW 60 million | KRW 175 million | 2 | 79 | |
| Genome & Company | KRW 60 million | KRW 189 million | 4 | 96 | Filer note attached |
| Ahn-Gook Pharmaceutical | KRW 59 million | KRW 695 million | 3 | 424 | |
| C&R Research | KRW 58 million | KRW 365 million | 3 | 522 | Filer note attached |
| Huons | KRW 58 million | KRW 279 million | 5 | 1,087 | |
| JIN Yang Pharmacetical | KRW 58 million | KRW 382 million | 3 | 219 | |
| Medpacto | KRW 58 million | KRW 175 million | 4 | 54 | |
| Tium Bio | KRW 58 million | KRW 267 million | 3 | 67 | |
| EN Cell | KRW 57 million | KRW 286 million | 3 | 112 | |
| Choong ANG Vaccine Laboratory | KRW 57 million | KRW 262 million | 4 | 194 | |
| Humedix | KRW 57 million | KRW 217 million | 4 | 377 | |
| Dong Koo Bio & Pharma | KRW 56 million | KRW 436 million | 4 | 440 | |
| Kyungdong Pharm | KRW 56 million | KRW 472 million | 3 | 363 | |
| Sam-A Pharm | KRW 56 million | KRW 299 million | 2 | 310 | |
| Korean Drug | KRW 56 million | KRW 348 million | 3 | 238 | |
| Telcon RF Pharmaceutical | KRW 56 million | KRW 88 million | 5 | 133 | |
| Kanaph Therapeutics | KRW 55 million | KRW 203 million | 3 | 23 | |
| Samik Pharm | KRW 55 million | KRW 242 million | 4 | 146 | |
| IT-Chem | KRW 55 million | KRW 103 million | 3 | 133 | |
| Dream CIS | KRW 55 million | KRW 179 million | 4 | 395 | Filer note attached |
| Vaxcell-Bio Therapeutics | KRW 55 million | KRW 212 million | 2 | 91 | |
| Abion | KRW 55 million | KRW 189 million | 4 | 34 | Filer note attached |
| Woo Gene B&G | KRW 54 million | KRW 253 million | 2 | 103 | |
| HLB Pharmaceutical | KRW 54 million | KRW 132 million | 4 | 185 | |
| Kyung NAM Pharm | KRW 54 million | KRW 45 million | 4 | 238 | |
| Optus Pharmaceutical | KRW 54 million | KRW 188 million | 2 | 250 | Filer note attached |
| Daebongls | KRW 54 million | KRW 189 million | 3 | 138 | |
| Future Chem | KRW 53 million | KRW 139 million | 4 | 94 | |
| Korea Arlico Pharm | KRW 53 million | KRW 371 million | 2 | 228 | |
| Vivozon Pharmaceutical | KRW 53 million | KRW 126 million | 2 | 292 | |
| Hana Pharm | KRW 53 million | KRW 283 million | 4 | 706 | |
| Withus Pharmaceutical | KRW 53 million | KRW 281 million | 3 | 220 | |
| Suheung | KRW 52 million | KRW 406 million | 3 | 1,295 | |
| Ilsung IS | KRW 52 million | KRW 317 million | 5 | 194 | |
| Olipass | KRW 52 million | KRW 91 million | 4 | 26 | |
| Polaris AI Pharma | KRW 51 million | KRW 434 million | 4 | 167 | |
| Cellbion | KRW 51 million | KRW 157 million | 2 | 56 | |
| Theragen Etex | KRW 51 million | KRW 194 million | 5 | 222 | |
| Aprogen | KRW 50 million | KRW 175 million | 2 | 311 | |
| Shinil Pharmaceutical | KRW 50 million | KRW 339 million | 3 | 413 | |
| Binex | KRW 49 million | KRW 358 million | 3 | 791 | |
| HLB Therapeutics | KRW 49 million | KRW 70 million | 3 | 50 | |
| Enzychem Lifesciences | KRW 49 million | KRW 766 million | 3 | 116 | |
| Eagle Veterinary Technology | KRW 48 million | KRW 112 million | 2 | 110 | |
| DAE HWA Pharm | KRW 48 million | KRW 548 million | 1 | 369 | Filer note attached |
| WSI | KRW 48 million | KRW 633 million | 3 | 29 | Holding-like flagged |
| Komipharm International | KRW 47 million | KRW 154 million | 4 | 172 | |
| Aprogen Biologics | KRW 47 million | KRW 227 million | 3 | 445 | |
| CTC BIO | KRW 47 million | KRW 340 million | 5 | 237 | Filer note attached |
| GL Pharm Tech | KRW 46 million | KRW 95 million | 2 | 32 | |
| Gene Bio Tech | KRW 45 million | KRW 83 million | 3 | 45 | |
| Daesung Microbiological Labs | KRW 45 million | KRW 203 million | 2 | 138 | |
| Duchem Bio | KRW 44 million | KRW 114 million | 2 | 144 | |
| Dongsung Pharmaceutical | KRW 43 million | KRW 167 million | 3 | 307 | |
| Aptocrom | KRW 43 million | KRW 395 million | 3 | 16 | Denominator mismatch flagged |
| Cellromax Science | KRW 41 million | KRW 304 million | 3 | 52 | |
| BC World Pharm | KRW 41 million | KRW 325 million | 3 | 288 | |
| MOA Life Plus | KRW 40 million | KRW 180 million | 4 | 54 | |
| Union Korea Pharm | KRW 39 million | KRW 59 million | 4 | 123 | |
| Adbiotech | KRW 39 million | KRW 76 million | 4 | 64 | Denominator mismatch flagged |
| RP Bio | KRW 38 million | KRW 155 million | 3 | 534 | |
| Prestige Biologics | KRW 37 million | KRW 97 million | 4 | 279 | Denominator mismatch flagged · Fiscal year end 06 |
| SLS Bio | KRW 36 million | KRW 67 million | 3 | 63 | |
| Anterogen | KRW 34 million | KRW 207 million | 3 | 32 | |
| TDS Pharm | KRW 32 million | KRW 306 million | 2 | 111 | |
| CXI Healthcare Technology Group | Foreign-incorporated listing | Foreign-incorporated listing | 3 | — | Fiscal year end 06 |
| Prestige Biopharma Limited KDR | Foreign-incorporated listing | Foreign-incorporated listing | 3 | 67 | Filer note attached · Fiscal year end 06 |
| Neo Immune Tech | Foreign-incorporated listing | Foreign-incorporated listing | 1 | 40 | Filer note attached · Denominator mismatch flagged |
| Samsung Epis Holdings | Value not displayed | KRW 676 million | 2 | 9 | Denominator mismatch flagged |
| Into Cell | Value not displayed | KRW 204 million | 3 | — |
Before reading this table
- The employee average divides the filed pay total by the filed headcount. The director average is the filed per-person average as it stands, so it can differ from that total divided by that headcount, and the divided figure replaces it only where the two are plainly at odds.
- Listed filers only, and consolidated subsidiaries' staff are not included.
- These figures come from filed data whose accuracy the source institution does not guarantee.
- Every pay figure in a company row comes only from that company's own business report. Where this site computes one, it uses only the totals and headcounts that same company filed and takes no amount from anywhere else.
- Where few registered directors are covered, the per-person average approaches a few individuals' pay.
- Sharing an industry code does not mean doing the same work.
- Filed values on the wrong digit scale are converted to a common basis against the company's own filings in other years, and where no basis exists the reason shows instead of an amount.
- Classifications with thin samples publish no median or other industry figure, while the employee average is shown regardless of sample size alongside the company count.
Industry groupings and names follow Naver Finance's sector classification. The per-company figures themselves come from each company's own annual-report filings.